Obesity is a chronic metabolic disease affecting adults and children worldwide. It has
become one of the leading causes of death, as obesity is known to be the main risk factor for …

Background: Schizophrenia is among the major causes of disability worldwide and the
mortality from cardiovascular disease (CVD) is significantly elevated. There is a growing …

Cognitive impairment is a core symptom domain of schizophrenia. The effect of
antipsychotics, the cornerstone of treatment in schizophrenia, on this domain is not fully …

Metabolic syndrome and other cardiovascular risk factors are highly prevalent in people with
schizophrenia. Patients are at risk for premature mortality and overall have limited access to …

The rise of the early intervention paradigm in psychotic disorders represents a maturing of
the therapeutic approach in psychiatry, as it embraces practical preventive strategies which …

Aim: The first-episode psychosis (FEP) represents a critical period to prevent cardiovascular
and metabolic morbidity decades later. Antipsychotic (AP)-induced weight gain is one …

Objectives: To assess the methods and reporting of cardiometabolic outcome studies of the
first treated episode of psychosis, review key findings, and suggest directions for future …

Despite treatment advances over the past decades, schizophrenia remains one of the most
severe psychiatric disorders that is associated with a chronic relapsing course and marked …

Antipsychotic-induced weight gain is an important issue in the treatment of psychotic
illnesses, and affects 80% of individuals being treated with antipsychotic drugs. However …

Objective: To provide an overview for practicing clinicians on the pharmacological basis of
cardiometabolic risk induced by antipsychotic drugs in patients with serious mental illness …